Allarity Therapeutics (ALLR) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ALLR Allarity Therapeutics

Watchlist

1.1000
-0.0100-0.90%

Close Nov 29 13:00 ET

1.1100
+0.0100+0.91%

Post 16:26 ET

4.88MMarket Cap-156P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Allarity Therapeutics Inc - Two Patients Exceed 14 Months on Treatment in Phase 2 Trial
ReutersNov 18 08:00 ET
Express News | Allarity Therapeutics Inc - Maintains Cash Balance of $18.5 Million
ReutersNov 18 08:00 ET
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
GlobeNewswireNov 18 08:00 ET
Allarity Therapeutics | 10-Q: Q3 2024 Earnings Report
SECNov 14 16:25 ET · Announcements
Express News | Allarity Therapeutics Q3 EPS $(7.71) Beats $(8.40) Estimate
BenzingaNov 14 08:28 ET
Allarity Therapeutics | 8-K: Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
SECNov 14 08:21 ET

Comments

Shroomie

Nov 27 15:39

look at all these bagholders in the 5 dollar range... amazing

$Allarity Therapeutics (ALLR.US)$

Jaguar8

Nov 18 09:48

NEWS PM

$Allarity Therapeutics (ALLR.US)$
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Allarity Therapeutics (NASDAQ: ALLR) reported significant progress in its Phase 2 stenoparib trial for advanced ovarian cancer, with two patients exceeding 14 months of treatment.
The company maintains a strong financial position with $18.5 million cash balance as of September 30, 2024, enabling advancement toward FDA approval. Additionally, Allarit...